Zobrazeno 1 - 10
of 22
pro vyhledávání: '"J R Murren"'
Publikováno v:
Histopathology. 49(2)
Aims: Most small cell lung carcinoma (SCLC) patientshave metastatic disease at the time of diagnosis andare faced with poor prognosis and limited treatmentoptions. Reports of HER-2/neu gene amplification andoverexpression in this malignancy have rai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc9a424a4f4b86a6ec9a50f8e2f263b
https://pubmed.ncbi.nlm.nih.gov/16879393
https://pubmed.ncbi.nlm.nih.gov/16879393
Autor:
A, Argiris, J R, Murren
Publikováno v:
Cancer journal (Sudbury, Mass.). 7(5)
The two-stage system introduced by the Veterans' Affairs Lung Study Group continues to be widely utilized in small-cell lung cancer (SCLC), mainly because of its simplicity and clinical utility. Approximately one third of patients with SCLC present w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::11b03536f319fcfb4840de7f44e28c01
https://pubmed.ncbi.nlm.nih.gov/11693903
https://pubmed.ncbi.nlm.nih.gov/11693903
Autor:
J R, Murren
Publikováno v:
Oncology (Williston Park, N.Y.). 15(7 Suppl 8)
During the past decade, five new cytotoxic drugs have been introduced that are active against non-small-cell lung cancer (NSCLC). These agents include vinorelbine (Navelbine), paclitaxel (Taxol), docetaxel (Taxotere), gemcitabine (Gemzar), and irinot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5054c27026ec57539c14fb5931951c07
https://pubmed.ncbi.nlm.nih.gov/11497229
https://pubmed.ncbi.nlm.nih.gov/11497229
Autor:
A, Argiris, J R, Murren
Publikováno v:
Cancer journal (Sudbury, Mass.). 7(3)
Small cell lung cancer (SCLC) is a common neoplasm with an extremely poor prognosis. Patients with extensive-stage disease have a 5-year survival rate of 1% to 2%. Identification of new active chemotherapy agents is of great importance for the develo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4ac6e8bc0c2209c11b757d323ffaa11f
https://pubmed.ncbi.nlm.nih.gov/11419031
https://pubmed.ncbi.nlm.nih.gov/11419031
Publikováno v:
Oncology (Williston Park, N.Y.). 15(1 Suppl 1)
Cisplatin (Platinol)-based chemotherapy has been the standard systemic therapy for both non-small-cell and small-cell lung cancer for the past 2 decades, though the efficacy and benefit remain modest. Recently, several novel agents have been introduc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::df10cb98b1b8b55008087abc878c8c2b
https://pubmed.ncbi.nlm.nih.gov/11221018
https://pubmed.ncbi.nlm.nih.gov/11221018
Publikováno v:
Cancer investigation. 18(7)
Advanced-stage cutaneous T-cell lymphoma (CTCL) is generally resistant to standard chemotherapy. Because P-glycoprotein (P-gp) has been detected in other types of resistant solid tumors, leukemias, and lymphomas, we analyzed P-gp expression in CTCL.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3efe26bd1b6707bd7ea07cf5b1ac69e7
https://pubmed.ncbi.nlm.nih.gov/11036468
https://pubmed.ncbi.nlm.nih.gov/11036468
Autor:
J R, Murren, S A, DiStasio, A, Lorico, A, McKeon, E G, Zuhowski, M J, Egorin, A C, Sartorelli, G, Rappa
Publikováno v:
Cancer journal (Sudbury, Mass.). 6(4)
The coumarin antibiotic novobiocin potentiates the activity of etoposide (VP-16) in vitro by increasing intracellular accumulation of VP-16. The drug efflux pump inhibited by novobiocin appears to be distinct from both of the major proteins associate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::60b0b0520f9afd4330aec3e315992bdb
https://pubmed.ncbi.nlm.nih.gov/11038146
https://pubmed.ncbi.nlm.nih.gov/11038146
Publikováno v:
Anti-cancer drug design. 15(2)
We have previously reported that novobiocin potentiates the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26) in a number of experimental tumor cell lines by inhibition of the efflux of the epipodophyllotoxins by an ATP-requiring transpo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::638a973c5515b0da56ea7b6581c3f15a
https://pubmed.ncbi.nlm.nih.gov/10901300
https://pubmed.ncbi.nlm.nih.gov/10901300
Publikováno v:
Seminars in oncology. 26(5 Suppl 16)
Single-agent activity has been observed for both docetaxel and irinotecan in several solid tumors, including non-small cell lung cancer (NSCLC). Compilation of data from phase II trials of single-agent docetaxel therapy in NSCLC yielded overall respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::09acbf81f87659bd4975164fb6663b8d
https://pubmed.ncbi.nlm.nih.gov/10585007
https://pubmed.ncbi.nlm.nih.gov/10585007
Autor:
J R, Murren, A, Gollerkeri, S, Anderson, S, Lutzker, S, Del Prete, D, Zelterman, L, Garrison, B, Smith
Publikováno v:
The Yale Journal of Biology and Medicine
PURPOSE: Treatment with hematopoietic growth factors increases the percentage of hematopoietic progenitor cells in cell cycle. Following withdrawal of certain growth factors, preclinical data suggest that there is a transient fall in the percentage o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::72d3de2f853e23501230c8a653e4ce0b
https://pubmed.ncbi.nlm.nih.gov/10527363
https://pubmed.ncbi.nlm.nih.gov/10527363